Alembic Pharmaceuticals Ltd. - Research Center
533573 APLLTD Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Sales | 4,132.55 | 3,660.27 | 2,945.26 | 2,956.45 | 2,991.74 |
| Operating profit | 1,202.90 | 878.67 | 632.53 | 633.28 | 982.01 |
| Interest | 25.19 | 14.87 | 2.22 | 3.09 | 2.36 |
| Gross profit | 1,312.46 | 870.22 | 636.98 | 632.61 | 985.16 |
| EPS (Rs) | 51.43 | 32.42 | 22.39 | 22.85 | 37.03 |
Annual
results in details
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Other income | 134.75 | 6.42 | 6.67 | 2.42 | 5.51 |
| Stock adjustment | -176.50 | -80.41 | -36.18 | -47.90 | -95.94 |
| Raw material | 978.13 | 850.05 | 725.75 | 703.87 | 642.24 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 806.37 | 684.45 | 582.72 | 527.46 | 404.31 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | 216.15 |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,321.65 | 1,327.51 | 1,040.44 | 1,139.74 | 842.97 |
| Provisions made | - | - | - | - | - |
| Depreciation | 135.67 | 105.59 | 101.76 | 82.90 | 71.86 |
| Taxation | 197.39 | 153.42 | 113.23 | 119.08 | 215.17 |
| Net profit / loss | 969.40 | 611.21 | 421.99 | 430.63 | 698.13 |
| Extra ordinary item | -10.00 | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 37.70 | 37.70 | 37.70 | 37.70 | 37.70 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 29.11 | 24.01 | 21.48 | 21.42 | 32.82 |
| GPM (%) | 30.76 | 23.73 | 21.58 | 21.38 | 32.87 |
| NPM (%) | 22.72 | 16.67 | 14.30 | 14.55 | 23.29 |
© 2021 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis